Tracers / [225Ac]Ac-DOTA-MSC3
[225Ac]Ac-DOTA-MSC3
Also written as [Ac-225]Ac-DOTA-MSC3
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- Monoclonal antibody (anti-CAIX antibody, DOTA-conjugated)
- Target / mechanism
- Carbonic anhydrase IX (CAIX), expressed on hypoxic tumor cells PMID 41799189
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/in111-dotamsc3/">in111-dotamsc3</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | 81% | DOTA-MSC3 | 41799189 2026 Theranostics Details regarding antibody conjugation, radiolabeling and cell culture are described in the supplemental methods. |
Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTA-MSC3, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41799189. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41799189: 'Monoclonal anti-CAIX antibody DOTA-MSC3 was labeled with indium-111 (111In) or actinium-225 (225Ac)'. Stage set/updated at stage 23 from PMID 41799189: 'Overall, these results demonstrate first proof-of-concept of the potential of CAIX-TAT to treat hypoxic tumors by targeting CAIX-positive hypoxic tumor regions.'.